RecruitingPHASE1, PHASE2NCT05470491

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Mustafa A Hyder, M.D.
National Cancer Institute (NCI)
Intervention
RIC(drug)
Enrollment
265 enrolled
Eligibility
12-120 years · All sexes
Timeline
20232027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05470491 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency

← Back to all trials